B
Beam Therapeutics D
D
BEAM
29.020
USD
2.19
(8.16%)
Market Closed
Volume
44,121
EPS
-5
Div Yield
-
P/E
-18
Market Cap
2,403,019,296
Novo Nordisk Surges in Profit and Sales
7 months ago
Stocks news More
Title: Beam Therapeutics
Sector: Healthcare
Industry: Biotechnology
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making adouble-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.